Skip to Main content Skip to Navigation
Master Thesis

Détection des mutations circulantes PIK3CA au diagnostic chez les patientes suivies pour un cancer du sein inflammatoire non métastatique

Abstract : Inflammatory breast cancer (IBC) is an aggressive BC subtype with rapid onset and poor outcomes. After biopsy confirmation, first-line treatment is based on systemic chemotherapy. A targetable somatic PIK3CA mutation is reported in 30% of IBC, allowing for treatment by PI3Kα-specific inhibitors, such as alpélisib. The aim of this study was to evaluate the detection rate of circulating PIK3CA mutation in non-metastatic IBC patients harbouring a PIK3CA mutation on initial biopsy. This monocentric retrospective study was based on available stored plasmas and biopsies at diagnosis and included all non-metastatic IBC patients who were treated by neo-adjuvant chemotherapy. PIK3CA mutations (E542K, E545K, H1047R/L) were assessed by droplet digital PCR (ddPCR) in plasma samples and tumoral tissue at diagnosis. A total of 55 patients treated between 2008 and 2018 in Henri Becquerel Center and with sufficient DNA from tumor tissue were included. 14/55 patients (25%) had a PIK3CA mutation identified on baseline biopsy (H1047R=8; H1047L=3; E545K=2; E542K=1). All mutations were single. Among them, 11 (79%) patients had enough circulating DNA for circulating mutations analyses. Corresponding circulating PIK3CA mutations were found in 6/11 patients (55%). Beside these 6 patients, no other circulating mutation was identified among the 43 patients with fully interpretable circulating and biopsy mutational analyses. Our results revealed no prognostic or predictive value of PIK3CA mutations at diagnosis of non-metastatic IBC but highlighted a prognostic value of cfDNA rate at diagnosis. Our study showed that corresponding circulating PIK3CA mutation was identified in 55% of non-metastatic IBC patients with baseline somatic PIK3CA mutation on tumor tissue while no circulating mutation was found among non-mutated PIK3CA patients. Further studies are needed to determine the prognostic and therapeutic impact of circulating PIK3CA mutation in IBC patients.
Document type :
Master Thesis
Complete list of metadata

https://dumas.ccsd.cnrs.fr/dumas-03011601
Contributor : Bibliothèque Santé <>
Submitted on : Wednesday, November 18, 2020 - 10:56:35 AM
Last modification on : Thursday, November 26, 2020 - 3:28:23 AM
Long-term archiving on: : Friday, February 19, 2021 - 6:54:06 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : 2021-11-18

Please log in to resquest access to the document

Identifiers

  • HAL Id : dumas-03011601, version 1

Citation

Violette Allouchery. Détection des mutations circulantes PIK3CA au diagnostic chez les patientes suivies pour un cancer du sein inflammatoire non métastatique. Médecine humaine et pathologie. 2020. ⟨dumas-03011601⟩

Share

Metrics

Record views

68